Bipolar Disorder Treatment in Maplewood, NJ

Bipolar disorder is a chronic, recurrent mood disorder characterized by episodes of mania or hypomania that alternate with episodes of depression. It affects roughly 2.8% of U.S. adults in any given year and typically emerges in late adolescence or early adulthood — the median age of onset is 25. Despite how commonly the word gets used colloquially to describe moodiness or rapid emotional shifts, bipolar disorder is a specific clinical condition with defined DSM-5-TR criteria, identifiable neurobiology, and well-established treatment pathways.

The stakes of getting bipolar care right are high. Roughly one in three patients with bipolar disorder will make a lifetime suicide attempt¹ — one of the highest rates in all of psychiatry — and lifetime suicide mortality is substantially elevated. Untreated or under-treated bipolar disorder also produces cumulative cognitive and functional impact across decades, with each unmanaged episode potentially contributing to more severe future presentations. On the other hand, well-managed bipolar disorder is compatible with full functioning, career stability, and satisfying relationships for most patients. The difference is the quality and consistency of care.

This page covers what we do at our Maplewood office and over NJ-wide telehealth: diagnostic workup with the diagnostic humility bipolar requires, first-line mood stabilizer pharmacotherapy, when and how to use antidepressants safely, psychotherapy coordination with IPSRT and FFT, monitoring protocols, lifestyle foundations that meaningfully reduce relapse, and crisis planning. Bipolar disorder is specifically named in Teresa's clinical focus — it is not a condition we see occasionally; it is one we see and treat week in and week out.

Bipolar disorder diagnosis is harder than most psychiatric diagnoses for a structural reason: patients rarely come in during a manic or hypomanic episode. They come in during depression, because depression is what makes people seek help. That means the diagnosis often requires careful retrospective reconstruction of prior mood states — a conversation that takes time and benefits from collateral input from family members who have observed the patterns.

The Mood Disorder Questionnaire (MDQ)is the most widely used bipolar screener — 13 yes/no items about past manic or hypomanic symptoms, with a positive screen requiring at least seven “yes” answers clustered in the same period plus some functional impact. Its sensitivity is about 0.73 and specificity about 0.90 — meaning it catches most bipolar cases but can miss some (especially subtler bipolar II presentations), and a positive MDQ should always prompt further evaluation rather than a reflexive diagnosis. We administer the MDQ on every depression intake precisely because bipolar II frequently presents as treatment-resistant depression, and the MDQ catches cases that would otherwise be missed.

The DSM-5-TR criteria themselves are the final arbiter. For each suspected manic or hypomanic episode, we walk through the specific symptom criteria (persistent elevated/irritable mood plus at least three — or four if only irritable — of the B-criteria symptoms: grandiosity, decreased need for sleep, pressured speech, racing thoughts, distractibility, increased activity, risky behavior), duration (7+ days for mania, 4+ days for hypomania), and functional impact (severe for mania, observable but less impairing for hypomania). Family input — from a spouse, parent, or sibling who has observed prior episodes — adds significant clarifying value when patients don't recognize their own episodes as abnormal.

Diagnostic humility is essential. When the picture is ambiguous — which it often is early — we name the ambiguity explicitly (“we're considering recurrent major depression versus bipolar II; the next 3–6 months of observation will help clarify”) and make conservative treatment choices that don't prejudge the answer.

Beyond quetiapine, several other atypical antipsychotics have FDA indications or strong evidence in bipolar disorder. Lurasidone (Latuda) has strong evidence for bipolar depression with a relatively favorable metabolic profile. Aripiprazole (Abilify) and cariprazine (Vraylar) are used for maintenance and mania. Olanzapine (Zyprexa) has strong efficacy but the heaviest metabolic burden and is often reserved for cases where other options have failed. Olanzapine-fluoxetine combination (Symbyax) is FDA-approved specifically for bipolar depression.

Metabolic monitoring applies to all atypical antipsychotics: weight, waist circumference, fasting glucose, HbA1c, and lipid panel at baseline and annually, with more frequent checks during dose changes. Long-term use of higher-potency agents also warrants monitoring for extrapyramidal symptoms and tardive dyskinesia. Choice within the class is primarily driven by side-effect profile matched to patient-specific concerns (weight-gain tolerance, sedation, activating vs. sedating profile) rather than large efficacy differences.

Three bipolar-specific psychotherapies have strong evidence and are typically referred alongside medication management. Cognitive Behavioral Therapy (CBT) adapted for bipolar disorder — typically 12–14 sessions — focuses on recognizing early warning signs of mood episodes, maintaining routines, challenging distorted thinking, and problem-solving functional impacts of the illness. CBT reduces depressive relapse and improves adherence to medication.

Interpersonal and Social Rhythm Therapy (IPSRT) is bipolar-specific and addresses the circadian and social-rhythm disruptions that commonly trigger mood episodes. Bipolar mood cycles are tightly linked to sleep-wake patterns, meal timing, light exposure, and social engagement. IPSRT teaches patients to track and stabilize these rhythms and has documented efficacy in reducing relapse.

Family-Focused Therapy (FFT) is a 21-session intervention specifically for bipolar patients and their families. It improves outcomes through psychoeducation about the illness, family communication training, and problem-solving skills. Studies show FFT can produce roughly 30–35% lower relapse rates compared to standard care. FFT is particularly valuable for younger patients (adolescents, young adults) living at home during a first or early episode, when family understanding of the illness shapes long-term trajectories.

Teresa provides brief supportive work and motivational support during medication visits. For structured CBT, IPSRT, or FFT, we refer to New Jersey-based specialists with the specific training and current openings. Group psychoeducation (Barcelona protocol, Systematic Care Management) is another evidence-based option when available.

Bipolar medication management includes standing laboratory monitoring that varies by medication but generally covers: basic metabolic panel (BMP), TSH and free T4, fasting glucose and HbA1c, fasting lipid panel, complete blood count (CBC), liver function tests (LFTs), pregnancy status in women of reproductive age, and drug levels for lithium and valproate. Baseline EKG is recommended for patients over 40 or with cardiovascular risk factors before starting certain atypical antipsychotics. Prolactin may be monitored for specific agents. For patients on carbamazepine in populations of Asian ancestry, HLA-B*1502 genetic testing is recommended before starting due to an elevated Stevens-Johnson syndrome risk.

Frequency is typically: baseline workup at initiation, 3-month recheck for drug levels and organ-function tests during dose titration, and 6-monthly intervals once stable. We order labs through your preferred laboratory and incorporate the results into visit planning. Cardiovascular screening is particularly important because bipolar disorder is associated with roughly twice the general-population rate of cardiovascular disease, partly due to metabolic side effects of medications and partly due to the underlying illness itself.

Suicide risk in bipolar disorder is substantial — roughly one in three patients will make a lifetime suicide attempt, with particularly elevated risk during depressive episodes, mixed features, early in treatment, and during significant life transitions. We take this seriously by building explicit safety planning into care: identifying personal warning signs, reducing access to means during high-risk periods, involving family members with patient consent, and establishing clear escalation pathways.

If you are in crisis right now: call or text 988 (Suicide & Crisis Lifeline) any time, day or night — free, confidential, staffed by trained counselors. If you are in immediate physical danger or unable to keep yourself safe, call 911 or go to the nearest emergency room. In New Jersey, NJ Hopeline (1-855-654-6735) is a state-specific option, and each county has a Psychiatric Emergency Screening Service (PESS) for in-person mobile crisis response. Our clinic is not a 24/7 crisis service; we follow up at the next scheduled visit and coordinate with crisis teams when a crisis episode has occurred.

Lithium's well-documented suicide-reduction effect is one of the reasons we recommend it over alternative mood stabilizers when clinically appropriate. The 50% reduction in completed suicide is one of the strongest treatment effects in all of medicine and factors heavily into the risk-benefit discussion at the time of prescribing.

Bipolar disorder is explicitly named in Teresa's clinical focus — it is a condition we see frequently and treat with the depth it requires. Initial evaluation is 60–90 minutes, covering DSM-5-TR criteria across the bipolar spectrum, MDQ screening, detailed mood-episode history with family input when available, medical history, medication history, substance use, and suicide-risk assessment with the Columbia Suicide Severity Rating Scale. Baseline laboratory workup is ordered as indicated.

Follow-up cadence during initial titration is every 2–4 weeks. Once stable on an effective regimen, visits move to every 4–8 weeks for the first year and every 2–3 months thereafter, with standing 6-monthly laboratory monitoring. Visits are substantive: 30–45 minutes that cover mood symptoms, sleep and circadian status, medication tolerance, lab review, life stressors, and any concerning cycling patterns. The PMHNP model allows prescribing and brief supportive therapy in the same visit; for structured CBT, IPSRT, or FFT, we refer and coordinate with NJ-based specialists.

Hybrid telehealth and in-person care works well for most stable bipolar patients. Initial evaluations and periodic check-in visits often benefit from the in-person format; routine medication management, therapy coordination, and rapid-contact visits during warning-sign periods are well-suited to telehealth. For patients with a history of rapid destabilization, we lean toward more frequent in-person contact.